Literature DB >> 31578639

When one cannot see the forest for the trees: femoral dP/dtmax, LVEF and pulse pressure in critically ill patients.

S Vaquer1,2,3,4, D Chemla5,6, X Monnet6,7.   

Abstract

Entities:  

Year:  2019        PMID: 31578639      PMCID: PMC6775176          DOI: 10.1186/s13613-019-0586-8

Source DB:  PubMed          Journal:  Ann Intensive Care        ISSN: 2110-5820            Impact factor:   6.925


× No keyword cloud information.

Dear Editor,

Whether the peak rate of pressure rise (dP/dtmax) in peripheral arteries is influenced by left ventricular (LV) contractility or by loading conditions remains controversial. We, therefore, appreciate the letter by Monge-García et al. [1] and have read it with interest. Our colleagues challenge the use of LV ejection fraction (LVEF) as a marker of LV systolic function and its comparison with femoral dP/dtmax to assess the reliability of the femoral dP/dtmax to track changes in LV contractility [1]. We entirely agree that LVEF is not a pure marker of LV contractility, as widely documented by others [2], and as clearly acknowledged in the discussion section of our article [3]. Furthermore, we agree that the invasive measure, LV end-systolic elastance (Ees), is the gold standard methodology to estimate LV contractility, but we were unable to measure it for ethical and technical reasons. In our paper [3], we presented LVEF data, as is commonly done in similar studies, but in contrast to the inference of our colleagues’ letter [1], our conclusion was not based upon LVEF results. In our study [3], we measured femoral dP/dtmax by pulse contour analysis before and after varying, LV systolic function (dobutamine infusion), preload (volume expansion and passive leg-raising) and afterload (norepinephrine) in 19 critically ill patients with cardiovascular failure [3]. Femoral dP/dtmax changed, not only in response to dobutamine infusion, but also following changes in cardiac loading, particularly following changes in afterload induced by variations in norepinephrine dose. In addition, changes in femoral dP/dtmax were strongly related to changes in arterial pulse pressure (PP) in each intervention and when all interventions were pooled (each R > 0.90). Interestingly, Sharman et al. have also documented strong associations between radial dP/dtmax and brachial PP in various populations of non-critically ill patients [4, 5]. Since PP is mainly influenced by arterial stiffness and stroke volume, and given the fact that PP explained > 80% of the variance of femoral dP/dtmax, we concluded that femoral dP/dtmax was mainly influenced by pulsatile arterial load [3]. These findings suggest that femoral dP/dtmax is highly sensitive to changes in loading conditions, especially afterload, and thus may not be directly interchangeable with LV contractility. In previous work [6], our colleagues have documented a linear relationship between Ees and femoral dP/dtmax in 10 anesthetized pigs during different loading and contractile conditions. However, while the authors present good concordance results, the strength of this relationship was rather moderate (R2 = 0.33) [6]. To our knowledge, the only other experimental study documenting the link between contractility (Ees) and femoral dP/dtmax is Morimont et al. [7] who studied 6 anesthetized and mechanically ventilated pigs after endotoxin-induced shock and norepinephrine infusion. In their work, authors reported that Ees and femoral dP/dtmax were significantly, albeit weakly correlated (R = 0.51, i.e., R2 = 0.26). Therefore, two independent experimental studies have documented that factors other than LV contractility (Ees) explain the vast majority (67% to 74%) of the variance of femoral dP/dtmax in response to LV contractility and ventricular loading changes [6, 7]. In conclusion, our results showed that changes in femoral dP/dtmax are essentially analogous to changes in femoral PP and therefore subject to the same dependence to variations in cardiac loading conditions, especially pulsatile arterial load. Our hypothesis is consistent with the previous results obtained at the upper arm level in non-critically ill patients [4, 5] and with results from two independent experimental studies, having failed to demonstrate strong correlation between LV contractility (Ees) and femoral dP/dtmax in various experimental settings [6, 7].
  6 in total

1.  Re: Tartière et al, Noninvasively determined radial dP/dt is a predictor of mortality in patients with heart failure (Am Heart J 2008;155:758-63).

Authors:  James E Sharman; Thomas H Marwick
Journal:  Am Heart J       Date:  2008-07-18       Impact factor: 4.749

Review 2.  Ejection fraction revisited.

Authors:  J L Robotham; M Takata; M Berman; Y Harasawa
Journal:  Anesthesiology       Date:  1991-01       Impact factor: 7.892

3.  Radial pressure waveform dP/dt max is a poor indicator of left ventricular systolic function.

Authors:  J E Sharman; A M Qasem; L Hanekom; D S Gill; R Lim; T H Marwick
Journal:  Eur J Clin Invest       Date:  2007-04       Impact factor: 4.686

4.  Arterial dP/dtmax accurately reflects left ventricular contractility during shock when adequate vascular filling is achieved.

Authors:  Philippe Morimont; Bernard Lambermont; Thomas Desaive; Nathalie Janssen; Geoffrey Chase; Vincent D'Orio
Journal:  BMC Cardiovasc Disord       Date:  2012-03-01       Impact factor: 2.298

5.  Influence of changes in ventricular systolic function and loading conditions on pulse contour analysis-derived femoral dP/dtmax.

Authors:  Sergi Vaquer; Denis Chemla; Jean-Louis Teboul; Umar Ahmad; Flora Cipriani; Joan Carles Oliva; Ana Ochagavia; Antonio Artigas; Francisco Baigorri; Xavier Monnet
Journal:  Ann Intensive Care       Date:  2019-05-30       Impact factor: 6.925

6.  Performance comparison of ventricular and arterial dP/dtmax for assessing left ventricular systolic function during different experimental loading and contractile conditions.

Authors:  Manuel Ignacio Monge Garcia; Zhongping Jian; Jos J Settels; Charles Hunley; Maurizio Cecconi; Feras Hatib; Michael R Pinsky
Journal:  Crit Care       Date:  2018-11-29       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.